

Article

BDDE-inspired chalcone derivatives to fight bacterial and fungal infectious

Ana Jesus ^{1,2,†}, Fernando Durães ^{1,2,†}, Nikoletta Szemerédi ³, Joana Freitas-Silva ^{2,4}, Paulo Martins da Costa ^{2,4}, Eugénia Pinto ^{2,5}, Madalena Pinto ^{1,2}, Gabriella Spengler ³, Emília Sousa ^{1,2,*}, Honorina Cidade ^{1,2,*}

¹ Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; anaaimjesus@gmail.com (A.J.); fduraes5@gmail.com (F.D.); madalena@ff.up.pt (M.P.)

² CIIMAR—Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Avenida General Norton de Matos, 4450-208 Matosinhos, Portugal; joanafreitasdasilva@gmail.com (J.F.-S.); pmcosta@icbas.up.pt (P.M.D.C.) epinto@ff.up.pt (E.P.)

³ Department of Medical Microbiology, Albert Szent-Györgyi Health Center and Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis utca 6, 6725 Szeged, Hungary; szemeredi.nikoletta@med.u-szeged.hu (N.S.), spengler.gabriella@med.u-szeged.hu (G.S.)

⁴ ICBAS – Institute of Biomedical Sciences Abel Salazar, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal

⁵ Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal;

[†] These authors contributed equally to this work and share first authorship.

^{*} Corresponding authors: esousa@ff.up.pt (E.S.); hcidade@ff.up.pt (H.C.).



Supplementary material

Table of contents:

NMR spectra and characterization of the compounds 1 , 3 , 4 , 6 , 9 , 10 , 13-16 , 18 , and 20	1
Figure S1. ¹ H NMR and ¹³ C NMR spectra of compound 1	1
Figure S2. HSQC and HMBC spectra of compound 1	2
Figure S3. ¹ H NMR and ¹³ C NMR spectra of compound 3	3
Figure S4. HSQC and HMBC spectra of compound 3	4
Figure S5. ¹ H NMR and ¹³ C NMR spectra of compound 4	5
Figure S6. HSQC and HMBC spectra of compound 4	6
Figure S7. ¹ H NMR and ¹³ C NMR spectra of compound 6	7
Figure S8. HSQC and HMBC spectra of compound 6	8
Figure S9. ¹ H NMR and ¹³ C NMR spectra of compound 9	9
Figure S10. HSQC and HMBC spectra of compound 9	10
Figure S11. ¹ H NMR and ¹³ C NMR spectra of compound 10	11
Figure S12. HSQC and HMBC spectra of compound 10	12
Figure S13. ¹ H NMR and ¹³ C NMR spectra of compound 13	13
Figure S14. HSQC and HMBC spectra of compound 13	14

Figure S15. ^1H NMR and ^{13}C NMR spectra of compound 14 .	15
Figure S16. ^1H NMR and ^{13}C NMR spectra of compound 14 .	16
Figure S17. ^1H NMR and ^{13}C NMR spectra of compound 15 .	17
Figure S18. HSQC and HMBC spectra of compound 15 .	18
Figure S19. ^1H NMR and ^{13}C NMR spectra of compound 16 .	19
Figure S20. HSQC and HMBC spectra of compound 16 .	20
Figure S21. ^1H NMR and ^{13}C NMR spectra of compound 18 .	21
Figure S22. ^1H NMR and ^{13}C NMR spectra of compound 18 .	22
Figure S23. ^1H NMR and ^{13}C NMR spectra of compound 20 .	23
Figure S24. ^1H NMR and ^{13}C NMR spectra of compound 20 .	24
NMR and HRMS spectra of compounds 2, 5, 11, 12, 17, and 21-26.	25
Figure S25. ^1H NMR and ^{13}C NMR spectra of compound 2 .	25
Figure S26. HSQC and HMBC spectra of compound 2 .	26
Figure S27. ^1H NMR and ^{13}C NMR spectra of compound 5 .	27
Figure S28. HSQC and HMBC spectra of compound 5 .	28
Figure S29. HRMS spectrum of compound 5 .	29
Figure S30. ^1H NMR and ^{13}C NMR spectra of compound 11 .	30
Figure S31. HSQC and HMBC spectra of compound 11 .	31
Figure S32. HRMS spectrum of compound 11 .	32
Figure S33. ^1H NMR and ^{13}C NMR spectra of compound 12 .	33
Figure S34. HSQC and HMBC spectra of compound 12 .	34
Figure S35. HRMS spectrum of compound 12 .	35
Figure S36. ^1H NMR and ^{13}C NMR spectra of compound 17 .	36
Figure S37. HSQC and HMBC spectra of compound 17 .	37
Figure S38. HRMS spectrum of compound 17 .	38
Figure S39. ^1H NMR and ^{13}C NMR spectra of compound 21 .	39
Figure S40. HSQC and HMBC spectra of compound 21 .	40
Figure S41. HRMS spectrum of compound 21 .	41
Figure S42. ^1H NMR and ^{13}C NMR spectra of compound 22 .	42
Figure S43. HSQC and HMBC spectra of compound 22 .	43
Figure S44. HRMS spectrum of compound 22 .	44
Figure S45. ^1H NMR and ^{13}C NMR spectra of compound 23 .	45

Figure S46. HSQC and HMBC spectra of compound 23	46
Figure S47. HRMS spectrum of compound 23	47
Figure S48. ^1H NMR and ^{13}C NMR spectra of compound 24	48
Figure S49. HSQC and HMBC spectra of compound 24	49
Figure S50. HRMS spectrum of compound 24	50
Figure S51. ^1H NMR and ^{13}C NMR spectra of compound 25	51
Figure S52. HSQC and HMBC spectra of compound 25	52
Figure S53. HRMS spectrum of compound 25	53
Figure S54. ^1H NMR and ^{13}C NMR spectra of compound 26	54
Figure S55. HSQC and HMBC spectra of compound 26	55
Figure S56. HRMS spectrum of compound 26	56
Relative fluorescence index curves for compounds 9 – 26	57
Figure S57. Relative fluorescence index (RFI) of compound 9 , reserpine (positive control) and DMSO (negative control).....	57
Figure S58. RFI of compound 10 , reserpine (positive control) and DMSO (negative control).	57
Figure S59. RFI of compound 11 , reserpine (positive control) and DMSO (negative control).	58
Figure S60. RFI of compound 12 , reserpine (positive control) and DMSO (negative control).	58
Figure S61. RFI of compound 13 , reserpine (positive control) and DMSO (negative control).	59
Figure S62. RFI of compound 14 , reserpine (positive control) and DMSO (negative control).	59
Figure S63. RFI of compound 15 , reserpine (positive control) and DMSO (negative control).	60
Figure S64. RFI of compound 16 , reserpine (positive control) and DMSO (negative control).	60
Figure S65. RFI of compound 17 , reserpine (positive control) and DMSO (negative control).	61
Figure S66. RFI of compound 18 , reserpine (positive control) and DMSO (negative control).	61
Figure S67. RFI of compound 19 , reserpine (positive control) and DMSO (negative control).	62
Figure S68. RFI of compound 20 , reserpine (positive control) and DMSO (negative control).	62
Figure S69. RFI of compound 21 , reserpine (positive control) and DMSO (negative control).	63
Figure S70. RFI of compound 22 , reserpine (positive control) and DMSO (negative control).	63
Figure S71. RFI of compound 23 , reserpine (positive control) and DMSO (negative control).	64
Figure S72. RFI of compound 24 , reserpine (positive control) and DMSO (negative control).	64
Figure S73. RFI of compound 25 , reserpine (positive control) and DMSO (negative control).	65
Figure S74. RFI of compound 26 , reserpine (positive control) and DMSO (negative control).	65
Figure S75. Chalcones described in [10], used in the docking studies.....	66
Docking studies	66

NMR spectra and characterization of the compounds **1**, **3**, **4**, **6**, **9**, **10**, **13-16**, **18**, and **20**.Figure S1. ¹H NMR and ¹³C NMR spectra of compound **1**.




Figure S2. HSQC and HMBC spectra of compound **1**.

2-bromo-4,5-dimethoxybenzaldehyde (1): Purified by flash column chromatography (SiO₂, n-hexane: ethyl acetate 9:1). Yield: 49% as a white solid; m.p.(n-hexane / ethyl acetate 9:1) = 150.7 - 151.5 °C; IR (KBr, ν (cm⁻¹)): 3008 (Csp₂-H); 2979, 2919, 2849 (Csp₃-H); 1669 (C=O); 1590, 1507, 1469, 1445 (aromatic C=C), 1218 (C-O); 589 (C-Br); ¹H NMR (300 MHz, CDCl₃) δ (ppm): 10.18 (s, CHO), 7.41 (s, H-6), 7.05 (s, H-3), 3.96 (s, 5- OCH₃), 3.92 (4-OCH₃); ¹³C NMR (300 MHz, CDCl₃) δ (ppm): 190.8 (C=O), 154.5 (C-5), 148.8 (C-4), 120.4 (C-2), 115.5 (C-3), 110.4 (C-6), 56.5 (5-OCH₃), 56.2 (4-OCH₃).




Figure S3. ¹H NMR and ¹³C NMR spectra of compound 3.




Figure S4. HSQC and HMBC spectra of compound 3.

5-bromo-2,3-dimethoxybenzaldehyde (3): purified by flash column chromatography (SiO₂, n-hexane: ethyl acetate 9:1). Yield: 53% as white solid; m.p. (n-hexane/ethyl acetate 95:5) = 77.8 - 80.4°C; IR (KBr, ν (cm⁻¹)): 3082 (C_{sp2}-H); 2966, 2939, 2847 (C_{sp3}-H); 1679 (C=O); 1577, 1482, 1445, 1429 (aromatic C=C); 1218 (C-O); 583 (C-Br); ¹H NMR (300 MHz, CDCl₃) δ (ppm): 10.34 (s, CHO), 7.53 (d, J = 2.3 Hz, H-4), 7.22 (d, J = 2.3 Hz, H-6), 3.97 (s, 2-OCH₃), 3.90 (s, 3-OCH₃); ¹³C NMR (300 MHz, CDCl₃) δ (ppm): 188.7 (C=O), 153.9 (C-3), 151.9 (C-2), 121.8 (C-4), 121.0 (C-6), 117.0 (C-5), 62.4 (2-OCH₃), 56.3 (3-OCH₃).




Figure S5. ¹H NMR and ¹³C NMR spectra of compound 4.




Figure S6. HSQC and HMBC spectra of compound 4.

2-bromo-4,5-dimethoxyacetophenone (4): purified by flash column chromatography (SiO₂, n-hexane: ethyl acetate 9:1). Yield: 63% as white solid; m.p. (n-hexane/ethyl acetate 9:1) = 74.7 - 75.6 °C; IR (KBr, ν (cm⁻¹)): 2967, 2937, 2841 (C_{sp^3} -H); 1681 (C=O); 159, 1562, 1501, 1440 (aromatic C=C); 1204 (C-O); 649 (C-Br); ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.14 (s, H-6), 7.05 (s, H-3), 3.92 (s, 5-OCH₃), 3.89 (4-OCH₃), 2.67 (s, H-1'); ¹³C NMR (300 MHz, CDCl₃) δ (ppm): 199.5 (C=O), 151.6 (C-5), 148.2 (C-4), 132.7 (C-1), 116.4 (C-3), 112.6 (C-6), 111.8 (C-2), 56.4 (5-OCH₃), 56.2 (4-OCH₃, 30.5 (C-1').




Figure S7. ¹H NMR and ¹³C NMR spectra of compound 6.




Figure S8. HSQC and HMBC spectra of compound 6.

2,3-dibromo-4,5-dimethoxyacetophenone (6): purified by flash column chromatography (SiO₂, n-hexane: ethyl acetate 95:5). Yield: 1% as orange oil; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.18 (s, H-6), 3.87 (s, 5-OCH₃), 3.80 (s, 4-OCH₃), 2.51 (s, H-1'); ¹³C NMR (300 MHz, CDCl₃) δ (ppm): 200.7 (C=O), 152.5 (C-4), 144.7 (C-5), 139.5 (C-1), 120.0 (C-2), 117.3 (C-6), 109.3 (C-6), 62.0 (5-OCH₃), 56.3 (4-OCH₃), 31.2 (C-1').




Figure S9. ^1H NMR and ^{13}C NMR spectra of compound **9**.




Figure S10. HSQC and HMBC spectra of compound 9.

(E)-1,3-bis(2-bromo-4,5-dimethoxyphenyl)prop-2-en-1-one (9): purified by flash column chromatography (SiO₂, n-hexane/ ethyl acetate 98:2), followed by TLC (SiO₂, diethyl ether/ petroleum ether 8:2). Yield: 87% as yellow solid; m.p.(diethyl ether/ petroleum ether 8:2) = 168.6 - 171.6 °C; IR (KBr, ν (cm⁻¹)): 2932, 1840 (C_{sp3}-H); 1658 (C=O); 1591, 1505, 1465, 1442 (aromatic C=C); 1336 (*trans* vinylic system); 1202 (C-O); 587 (C-Br); ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.83 (d, J = 15.9 Hz, H-β), 7.17 (s, H-3), 7.09 (s, H-6'), 7.06 (s, H-6), 7.03 (s, H-3'), 7.00 (d, J = 15.9 Hz, H-α), 3.94 (s, 5'-OCH₃), 3.92 (s, 4-OCH₃), 3.91 (s, 4'-OCH₃), 3.90 (s, 5-OCH₃); ¹³C NMR (300 MHz, CDCl₃) δ (ppm): 193.5 (C=O), 151.7 (C-4), 151.1 (C-5'), 148.7 (C-4'), 148.3 (C-5), 144.1 (C-β), 132.9 (C-1'), 126.6 (C-1), 126.5 (C-α), 118.1 (C-2), 116.0 (C-6'), 115.7 (C-6), 112.5 (C-3'), 111.2 (C-2'), 109.5 (C-3), 56.4 (4-OCH₃), 56.3 (5'-OCH₃), 56.2 (5-OCH₃), 56.1 (4'-OCH₃).




Figure S11. ¹H NMR and ¹³C NMR spectra of compound **10**.




Figure S12. HSQC and HMBC spectra of compound 10.

(E)-1-(2-bromo-4,5-dimethoxyphenyl)-3-(3,4-dimethoxyphe nyl)prop-2-en-1-one (10): purified by TLC (SiO_2 , n-hexane/ethyl acetate 9:1). Yield: 80% as yellow solid; m.p. (n-hexane/ethyl acetate 9:1) = 144.6–146.9 °C; IR (KBr, ν (cm⁻¹)): 3084 ($\text{C}_{\text{sp}2}$ -H); 2994, 2934, 2836 ($\text{C}_{\text{sp}3}$ -H); 1638 (C=O); 1596, 1514, 1451, 1442 (aromatic C=C); 1372 (*trans* vinylic system); 1229 (C-O); 578 (C-Br); ¹H NMR (300 MHz, CDCl_3) δ (ppm): 7.45 (*d*, J = 15.8 Hz, H-β), 7.17 (*dd*, J = 8.2; 2.1 Hz, H-6), 7.10 (*d*, J =2.1 Hz, H-2), 7.08 (*s*, H-3'), 7.04 (*d*, J = 15.8 Hz, H-α), 7.00 (*s*, H-6'), 6.89 (*d*, J = 8.2 Hz, H-5), 3.93 (*s*, 4-OCH₃), 3.92 (*s*, 3-OCH₃, 5'-OCH₃), 3.89 (*s*, 4'-OCH₃); ¹³C NMR (300 MHz, CDCl_3) δ (ppm): 193.6 (C=O), 151.6 (C-5'), 151.0 (C-4), 149.3 (C-3), 148.3 (C-4'), 145.7 (C-β), 133.5 (C-1'), 127.6 (C-α), 124.1 (C-6), 123.4 (C-1), 115.9 (C-3'), 112.3 (C-6'), 111.1 (C-2'), 111.0 (C-5), 110.0 (C-2), 56.4 (5'-OCH₃), 56.2 (4'-OCH₃), 56.0 (3-OCH₃), 55.9 (4-OCH₃).




Figure S13. ¹H NMR and ¹³C NMR spectra of compound 13.




Figure S14. HSQC and HMBC spectra of compound 13.

(E)-1,3-bis(3,4-dimethoxyphenyl)prop-2-en-1-one (13): Yield: 74% as a yellow solid; m.p. (distilled water) = 89.3 - 91.1 °C; IR (KBr, ν (cm⁻¹)): 3082, 3008 (C_{sp2}-H); 2937, 2839 (C_{sp3}-H); 1651 (C=O); 1597, 1574, 1510, 1464 (aromatic C=C); 1348 (*trans* vinylic system); 1200 (C-O); ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.77 (d, J = 15.5 Hz, H-β), 7.69 (dd, J = 8.5; 2.0 Hz, H-6'), 7.63 (d, J = 2.0 Hz, H-2'), 7.42 (d, J = 15.5 Hz, H-α), 7.25 (dd, J = 8.4; 1.9 Hz, H-6), 7.17 (d, J = 1.9 Hz, H-2), 6.94 (d, J = 8.5 Hz, H-5'), 6.91 (d, J = 8.4 Hz, H-5), 3.98 (s, 4'-OCH₃; 4-OCH₃), 3.96 (s, 3-OCH₃), 3.94 (s, 3'-OCH₃); ¹³C NMR (300 MHz, CDCl₃) δ (ppm): 188.7 (C=O), 153.1 (C-4'), 151.3 (C-4), 149.2 (C-3), 149.2 (C-3'), 144.2 (C-β), 131.6 (C-1'), 128.1 (C-1), 122.9 (C-6'; C-6), 119.6 (C-α), 111.1 (C-5), 110.8 (C-2'), 110.2 (C-2), 109.9 (C-5'), 56.1 (3'-OCH₃, 3-OCH₃), 56.0 (4-OCH₃), 55.9 (4'-OCH₃).




Figure S15. ¹H NMR and ¹³C NMR spectra of compound **14**.




Figure S16. ¹H NMR and ¹³C NMR spectra of compound 14.

(E)-1,3-bis(2,3-dimethoxyphenyl)prop-2-en-1-one (14): purified by flash column chromatography (SiO₂, n-hexane/ethyl acetate 9:1). Yield: 85% as an orange oil; IR (KBr, ν (cm⁻¹)): 3075 (C_{sp²}-H); 2937, 2836 (C_{sp³}-H); 1735 (C=O); 1652, 1576, 1474, 1426 (aromatic C=C); 1372 (*trans* vinylic system); 1170 (C-O); ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.94 (d, J = 16.1 Hz, H- β), 7.40 (d, J = 16.1 Hz, H- α), 7.24 (dd, J = 8.0; 2.2 Hz, H-6), 7.17 (dd, J = 7.7; 2.3 Hz, H-6), 7.13 (t, J = 7.7 Hz, H-5'), 7.06 (t, J = 8.0 Hz, H-5), 7.06 (dd, J = 7.7; 2.3 Hz, H-4'), 6.95 (dd, J = 8.0; 2.2 Hz, H-4), 3.91 (s, 3-OCH₃), 3.88 (s, 3'-OCH₃), 3.85 (s, 2-OCH₃, 2'-OCH₃); ¹³C NMR (300 MHz, CDCl₃) δ (ppm): 193.5 (C=O), 153.2 (C-3'), 153.0 (C-3), 148.9 (C-2'), 148.1 (C-2), 138.2 (C- β), 134.6 (C-1'), 129.1 (C-1), 128.0 (C- α), 124.2 (C-5', C-5), 121.1 (C-6'), 119.5 (C-6), 115.1 (C-4'), 114.1 (C-4), 62.0 (2'-OCH₃), 61.4 (2-OCH₃), 56.1 (3-OCH₃), 55.9 (3'-OCH₃).




Figure S17. ¹H NMR and ¹³C NMR spectra of compound **15**.




Figure S18. HSQC and HMBC spectra of compound 15.

(E)-2-(3,4-dimethoxybenzylidene)-6,7-dimethoxy-3,4-dihydronaphthalen-1(2H)-one (15): Yield: 54% as a yellow solid; m.p. (distilled water) = 142.9 - 144 °C; IR (KBr, ν (cm⁻¹)): 2990, 2937, 2837 (C_{sp^3} -H); 1657 (C=O); 1584, 1514, 1466, 1450 (aromatic C=C); 1362 (*trans* vinylic system); 1204 (C-O); ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.78 (s, H- β), 7.63 (s, H-2'), 7.07 (dd, J = 8.3; 1.9 Hz, H-6), 6.98 (d, J = 1.9 Hz, H-2), 6.91 (d, J = 8.3 Hz, H-5), 6.68 (s, H-5'), 3.95 (s, 3'-OCH₃), 3.94 (s, 4'-OCH₃), 3.92 (s, 4-OCH₃), 3.91 (s, 3-OCH₃), 3.15 (t, J = 6.5 Hz, H-1''), 2.90 (t, J = 6.5 Hz, H-2''); ¹³C NMR (300 MHz, CDCl₃) δ (ppm): 186.7 (C=O), 153.4 (C-4'), 149.4 (C-4), 148.7 (C-3), (148.2 (C-3'), 138.0 (C-1'), 136.2 (C- β), 133.8 (C-6'), 128.8 (C-1), 126.7 (C- α), 123.1 (C-6), 113.2 (C-2), 110.9 (C-5), 109.6 (C-2'), 109.6 (C-5'), 56.1 (3'-OCH₃, 4'-OCH₃), 56.0 (3-OCH₃, 4-OCH₃), 28.6 (C-2''), 27.6 (C-1'').




Figure S19. ¹H NMR and ¹³C NMR spectra of compound **16**.




Figure S20. HSQC and HMBC spectra of compound 16.

1,3-bis(3,4-dimethoxyphenyl)propan-1-one (16): purified by TLC (SiO₂, n-hexane/ ethyl acetate 6:4). Yield: 63% as a white solid; m.p. (n-hexane/ ethyl acetate 6:4) = 86.8 – 87.9 °C; IR (KBr, ν (cm⁻¹)): 3000 (C_{sp2}-H); 2964, 2938, 2839 (C_{sp3}-H); 1668 (C=O); 1591, 1515, 1470, 1456 (aromatic C=C), 1198 (C-O); ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.59 (d, J = 2.0 Hz, H-2'), 7.58 (dd, J = 8.4; 2.0 Hz, H-6'), 6.87 (d, J = 8.4 Hz, H-5'), 6.81 (d, J = 8.0 Hz, H-5), 6.78 (d, J = 2.6 Hz, H-2), 6.78 (dd, J = 8.0; 2.6 Hz, H-6), 3.94 (s, 4'-OCH₃), 3.93 (s, 4-OCH₃), 3.87 (s, 3'-OCH₃), 3.85 (s, 3-OCH₃), 3.24 (t, J = 7.6 Hz, H-β), 3.00 (t, J = 7.6 Hz, H-α); ¹³C NMR (300 MHz, CDCl₃) δ (ppm): 198.1 (C=O), 153.2 (C-4'), 149.0 (C-4), 148.9 (C-3'), 147.4 (C-3), 134.1 (C-1'), 130.1 (C-1), 122.7 (C-6'), 120.1 (C-2), 111.8 (C-6), 111.3 (C-5), 110.1 (C-2'), 110.0 (C-5'), 56.1 (4'-OCH₃; 4-OCH₃), 56.0 (3-OCH₃), 55.9 (3'-OCH₃), 40.3 (C-β), 30.2 (C-α).




Figure S21. ¹H NMR and ¹³C NMR spectra of compound **18**.




Figure S22. ^1H NMR and ^{13}C NMR spectra of compound 18.

2-(3,4-dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydronaphthalene-1(2H)-one (18): purified by TLC (SiO₂, n-hexane/ethyl acetate 7:3). Yield: 60% as a white solid; m.p. (n-hexane/ethyl acetate 7:3) = 139.5 – 140.1 °C; IR (KBr, ν (cm⁻¹)): 3083 ($\text{C}_{\text{sp}2}\text{-H}$); 2997, 2939, 2851, 2832 ($\text{C}_{\text{sp}3}\text{-H}$); 1659 ($\text{C}=\text{O}$); 1512, 1466, 1449, 1440 (aromatic C=C); 1181 (C-O); ^1H NMR (300 MHz, CDCl₃) δ (ppm): 7.54 (s, H-2'), 6.80 (dd, J = 7.6; 1.9 Hz, H-6), 6.78 (d, J = 7.6 Hz, H-6), 6.78 (d, J = 7.6 Hz, H-5), 6.74 (d, J = 1.9 Hz, H-2), 6.64 (s, H-5'), 3.92 (s, 3-OCH₃, 4-OCH₃), 3.87 (s, 4'-OCH₃), 3.86 (s, 3'-OCH₃), 3.39 (*m*, H- α), 2.80 (*t*, J = 4.8 Hz, H-1''), 2.63 (*m*, H- β a), 2.57 (*m*, H- β b), 2.10 (*m*, H-2''a), 1.77 (*m*, H-2''b); ^{13}C NMR (300 MHz, CDCl₃) δ (ppm): 198.1 (C=O), 153.2 (C-4'), 149.0 (C-4), 148.9 (C-3'), 147.4 (C-3), 134.1 (C-1'), 130.1 (C-1), 122.7 (C-6'), 120.1 (C-2), 111.8 (C-6), 111.3 (C-5), 110.1 (C-2'), 110.0 (C-5'), 56.1 (4'-OCH₃, 4-OCH₃), 56.0 (3-OCH₃), 55.9 (3'-OCH₃), 40.3 (C- β), 30.2 (C- α).




Figure S23. ^1H NMR and ^{13}C NMR spectra of compound **20**.




Figure S24. ^1H NMR and ^{13}C NMR spectra of compound 20.

1,3-bis(2,3-dimethoxyphenyl)propane (20): purified by TLC (SiO_2 , n-hexane/ethyl acetate 7:3). Yield: 66% as a colorless oil; IR (KBr, ν (cm^{-1})): 2934, 2860, 2833 ($\text{C}_{\text{sp}^3}\text{-H}$); 1598, 1584, 1474, 1429 (aromatic C=C); 1170 (C-O); ^1H NMR (300 MHz, CDCl_3) δ (ppm): 6.98 (t , $J = 8.1$ Hz, H-5'', H-5'), 6.80 (dd , $J = 8.1$; 1.7 Hz, H-6'', H-6'), 6.76 (dd , $J = 8.1$; 1.7 Hz, H-4'', H-4'), 3.85 (s , 3''-OCH₃, 3'-OCH₃), 3.80 (s , 2''-OCH₃, 2'-OCH₃), 2.70 (t , $J = 7.8$ Hz, H-1, H-3), 1.90 (m , H-2); ^{13}C NMR (300 MHz, CDCl_3) δ (ppm): 152.7 (C-3'', C-3'), 147.2 (C-2'', C-2'), 123.7 (C-5'', C-5'), 121.8 (C-6'', C-6'), 110.0 (C-4'', C-4'), 61.0 (2''-OCH₃, 2'-OCH₃), 55.7 (3''-OCH₃, 3'-OCH₃), 31.6 (C-2), 29.8 (C-1, C-3).

NMR and HRMS spectra of compounds 2, 5, 11, 12, 17, and 21-26.




Figure S25. ¹H NMR and ¹³C NMR spectra of compound 2.





Figure S26. HSQC and HMBC spectra of compound 2.




Figure S27. ¹H NMR and ¹³C NMR spectra of compound 5.





Figure S28. HSQC and HMBC spectra of compound 5.

230MABr2_2 #1-45 RT: 0.01-1.00 AV: 45 NL: 1.10E5
 F: FTMS + p ESI Full ms [300.00-400.00]



m/z calculated (ppm)	Formula	m/z found (ppm)	Error (ppm)
382.89762	C ₁₀ H ₁₀ Br ₂ O ₃ Na ₂	381.29904	-1.59858

Figure S29. HRMS spectrum of compound 5.




Figure S30. ^1H NMR and ^{13}C NMR spectra of compound **11**.





Figure S31. HSQC and HMBC spectra of compound 11.




Figure S32. HRMS spectrum of compound 11.




Figure S33. ¹H NMR and ¹³C NMR spectra of compound 12.





Figure S34. HSQC and HMBC spectra of compound 12.

23CR1_1 #1-59 RT: 0.01-1.00 AV: 59 NL: 1.51E6
F: FTMS + p ESI Full ms [100.00-2000.00]



m/z calculated (ppm)	Formula	m/z found (ppm)	Error (ppm)
486.95005	C ₁₉ H ₁₈ Br ₂ O ₅	486.95714	0.00709

Figure S35. HRMS spectrum of compound 12.




Figure S36. ¹H NMR and ¹³C NMR spectra of compound **17**.





Figure S37. HSQC and HMBC spectra of compound 17.



m/z calculated (ppm)	Formula	m/z found (ppm)	Error (ppm)
331.14672	C ₁₉ H ₂₂ O ₅	331.15394	0.00722

Figure S38. HRMS spectrum of compound **17**.




Figure S39. ¹H NMR and ¹³C NMR spectra of compound **21**.





Figure S40. HSQC and HMBC spectra of compound 21.



m/z calculated (ppm)	Formula	m/z found (ppm)	Error (ppm)
365.17288	$\text{C}_{21}\text{H}_{26}\text{O}_4\text{Na}$	365.17198	-0.0009

Figure S41. HRMS spectrum of compound 21.




Figure S42. ¹H NMR and ¹³C NMR spectra of compound 22.





Figure S43. HSQC and HMBC spectra of compound 22.



m/z calculated (ppm)	Formula	m/z found (ppm)	Error (ppm)
432.26577	C ₁₉ H ₂₁ BrO ₅ Na	431.04876	-1.21701

Figure S44. HRMS spectrum of compound 22.




Figure S45. ¹H NMR and ¹³C NMR spectra of compound 23.





Figure S46. HSQC and HMBC spectra of compound 23.



m/z calculated (ppm)	Formula	m/z found (ppm)	Error (ppm)
411.27600	C ₁₉ H ₂₃ BrO ₅	411.06331	-0.21269

Figure S47. HRMS spectrum of compound 23.




Figure S48. ¹H NMR and ¹³C NMR spectra of compound 24.




Figure S49. HSQC and HMBC spectra of compound 24.




Figure S50. HRMS spectrum of compound **24**.




Figure S51. ¹H NMR and ¹³C NMR spectra of compound 25.





Figure S52. HSQC and HMBC spectra of compound 25.



m/z calculated (ppm)	Formula	m/z found (ppm)	Error (ppm)
474.98644	$C_{19}H_{23}Br_2O_4$	474.99484	0.00840

Figure S53. HRMS spectrum of compound 25.



Figure S54. ¹H NMR and ¹³C NMR spectra of compound 26.





Figure S55. HSQC and HMBC spectra of compound 26.



m/z calculated (ppm)	Formula	m/z found (ppm)	Error (ppm)
474.98644	C ₁₉ H ₂₃ Br ₂ O ₄	474.99543	0,00899

Figure S56. HRMS spectrum of compound **26**.


Relative fluorescence index curves for compounds 9 – 26

Figure S57. Relative fluorescence index (RFI) of compound **9**, reserpine (positive control) and DMSO (negative control).




Figure S58. RFI of compound **10**, reserpine (positive control) and DMSO (negative control).




Figure S59. RFI of compound **11**, reserpine (positive control) and DMSO (negative control).




Figure S60. RFI of compound **12**, reserpine (positive control) and DMSO (negative control).




Figure S61. RFI of compound **13**, reserpine (positive control) and DMSO (negative control).




Figure S62. RFI of compound **14**, reserpine (positive control) and DMSO (negative control).




Figure S63. RFI of compound **15**, reserpine (positive control) and DMSO (negative control).




Figure S64. RFI of compound **16**, reserpine (positive control) and DMSO (negative control).




Figure S65. RFI of compound 17, reserpine (positive control) and DMSO (negative control).




Figure S66. RFI of compound 18, reserpine (positive control) and DMSO (negative control).




Figure S67. RFI of compound 19, reserpine (positive control) and DMSO (negative control).




Figure S68. RFI of compound 20, reserpine (positive control) and DMSO (negative control).




Figure S69. RFI of compound 21, reserpine (positive control) and DMSO (negative control).




Figure S70. RFI of compound 22, reserpine (positive control) and DMSO (negative control).




Figure S71. RFI of compound 23, reserpine (positive control) and DMSO (negative control).




Figure S72. RFI of compound 24, reserpine (positive control) and DMSO (negative control).




Figure S73. RFI of compound 25, reserpine (positive control) and DMSO (negative control).




Figure S74. RFI of compound 26, reserpine (positive control) and DMSO (negative control).




Figure S75. Chalcones described in [10], used in the docking studies.

Docking studies

Docking studies were performed in the NorA homology model, and the sites used for docking of the compounds were the binding core region (BCR) and the cytoplasmic side (CS), as described in [28] (**Table S1**).

Table S1. Docking results for the compounds in NorA (BCR: binding core region; CS: cytoplasmic side).

Name	Docking Score	
	BCR	CS
Reserpine	1.0	-4.6
9	-5.5	-5.2
10	-7.5	-5.6
11	-4.5	-4.8
12	-5.3	-5.3
13	-7.7	-7.3
14	-6.3	-5.2
15	-5.7	-5.6
16	-7.6	-7.5
17	-6.9	-5.1
18	-6.8	-5.6
22	-6.8	-6.8
23	-5.0	-4.9

24	-5.4	-5.6
19	-7.5	-7.4
20	-6.8	-5.1
21	-7.4	-7.2
25	-6.2	-6.1
26	-4.8	-4.5
a	-8.2	-4.4
b	-9.0	-4.6
c	-7.5	-4.9
d	-8.5	-4.6

From the analysis of the docking results, it can be noted that all the synthesized compounds are predicted to bind more effectively than reserpine in the sites tested, suggesting a possible potential for these compounds to act as EP inhibitors. However, it must be taken into account that a homology model of NorA is being used for the docking studies, and the results may not reflect the actual activity of the compounds. Nevertheless, all the compounds were tested for their potential as EP inhibitors.

Reference:

10. Rezende-Junior, L.M.; Andrade, L.M.S.; Leal, A.; Mesquita, A.B.S.; Santos, A.; Neto, J.S.L.; Siqueira-Junior, J.P.; Nogueira, C.E.S.; Kaatz, G.W.; Coutinho, H.D.M.; et al. Chalcones Isolated from Arrabidaea brachypoda Flowers as Inhibitors of NorA and MepA Multidrug Efflux Pumps of *Staphylococcus aureus*. *Antibiotics (Basel)* **2020**, *9*, doi:10.3390/antibiotics9060351.